Loading organizations...
§ Private Profile · Brussel, Belgium
Drug discovery company developing first-in-class GPCR-targeted medicines using ConfoBody® technology for structure-based drug design.
Confo Therapeutics is a Ghent, Belgium-based drug discovery company that develops medicines targeting G-protein coupled receptors (GPCRs) using proprietary single-domain antibody technology. The biotechnology firm utilizes its ConfoBody platform to stabilize proteins for structure-based drug design, successfully transitioning from a pure technology platform to advancing a proprietary clinical pipeline. Operating as a private entity, the company has completed four funding rounds to support its research and development efforts, including the initiation of a Phase 1 clinical trial for its lead candidate, CFTX-1554, an inhibitor aimed at treating neuropathic pain. Confo Therapeutics is backed by a syndicate of venture capital and institutional investors, including prominent life sciences investors such as Capricorn Venture Partners, VIB, PMV, and V-Bio Ventures. The Belgian enterprise was officially founded in 2015 by Jan Steyaert and Toon Laeremans as a spin-out from VIB-VUB.
Confo Therapeutics has raised $100.7M across 3 funding rounds.
Confo Therapeutics has raised $100.7M in total across 3 funding rounds.
Confo Therapeutics has raised $100.7M across 3 funding rounds. Most recently, it raised $65.0M Series B in July 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2024 | $65M Series B | Ackermans & VAN Haaren | BGV (biogeneration Ventures) | Announced |
| May 1, 2019 | $34M Series A | BGV (biogeneration Ventures) | — | Announced |
| Feb 1, 2017 | $1.7M Grant | — | — | Announced |
Confo Therapeutics has raised $100.7M in total across 3 funding rounds.
Confo Therapeutics's investors include Ackermans & van Haaren, BGV (BioGeneration Ventures).
Confo Therapeutics is a clinical-stage biotechnology company specializing in novel medicines targeting G-protein coupled receptors (GPCRs) for metabolic, endocrine, pain, and obesity-related diseases. Founded in 2015 as a spinout from VIB and Vrije Universiteit Brussel (VUB), it develops both small molecules and antibodies using its proprietary Confo® platform, which stabilizes GPCRs for drug discovery.[1][2][3][4] The company serves patients with challenging conditions like obesity and endocrine disorders, solving the problem of targeting "undruggable" GPCRs—key receptors involved in over 30% of approved drugs but historically difficult to modulate.[1][2] It has a partnered clinical-stage pain program (AT2R antagonist) with Eli Lilly, proprietary obesity candidates like GPR75 in lead optimization, and an in-house endocrine portfolio for orphan indications, demonstrating strong growth through grants (e.g., €1M VLAIO in 2025), partnerships, and a robust investor base including Perceptive Advisors and Wellington Partners.[1][2][4]
Confo Therapeutics emerged from groundbreaking academic research by Professor Jan Steyaert (VIB-VUB) and Nobel Laureate Professor Brian Kobilka (Stanford), who pioneered the stabilization of a GPCR in its active state—a breakthrough enabling structure-based drug design for this receptor family.[1][4] Spun out in 2015 by VIB (Flanders' Institute of Biotechnology) and VUB, the company started as a six-person team under CEO Cedric Ververken, leveraging VIB's New Ventures support and exclusive licenses to the "Steyaert patents" for GPCR technologies like Nb35.[1][2][4] A pivotal 2022 moment came when Confo resisted investor pressure to narrow focus solely to its pain program, preserving its broader platform for obesity and endocrine diseases, which fueled pipeline expansion and global ambitions.[1]
Confo rides the surging wave of GPCR therapeutics in biotech, where these receptors—central to diseases like obesity, pain, and endocrine disorders—represent a $100B+ market opportunity amid advances in structural biology and AI-driven design.[1][2][3] Timing is ideal post-2020s breakthroughs in cryo-EM and nanobody tech, amplified by post-pandemic focus on metabolic diseases (e.g., GLP-1 agonists' success highlighting GPCR potential).[1][2] Favorable forces include Belgium's biotech ecosystem (VIB/VLAIO support), big pharma's hunger for de-risked assets (e.g., Lilly deal), and a shift to multi-modality (small molecules + biologics) for durable therapies.[1][2][4] Confo influences the ecosystem by licensing tech, publishing (e.g., Nature), and partnering, accelerating GPCR drugging and inspiring spinouts in Flanders' life sciences hub.[1][4]
Confo is poised for milestone-driven catalysts, including obesity partnership deals and endocrine INDs, bolstered by its platform's expansion into next-gen antibodies for lifelong conditions.[1][2] Trends like multi-specific biologics, orphan drug incentives, and AI-enhanced GPCR screening will propel growth, potentially evolving Confo into a multi-asset player with pharma exits or IPO. As a leader unlocking GPCRs' power, it exemplifies how platform biotech spinouts transform undruggable targets into clinical realities.[1][3]